WHO Recommendations for the Prevention of Postpartum Haemorrhage Results from a WHO Technical Consultation October 18-20, 2006

Transcription

1 WHO Recommendations for the Prevention of Postpartum Haemorrhage Results from a WHO Technical Consultation October 18-20, 2006 Panel Presentation: M E Stanton, USAID; R Derman, UM/KC; H Sangvhi, JHPIEGO; D Armbruster, POPPHI/PATH

2 Background While there is general agreement on the beneficial effects of AMTSL, there are several unresolved issues: Clear definitions of components AMTSL under conditions of limited resources: Timing of uterotonic Drug to use Route of administration Can non-skilled providers use controlled cord traction?

3 Background Is early clamping of cord necessary? What does early mean? Suggestions to provide misoprostol where oxytocin not available to non-skilled providers and women themselves Concerns that misuse of misoprostol can lead to significant maternal morbidity and even death

4 Rationale for WHO Technical Consultation In light of these issues, WHO held a Technical Consultation on PPH in Geneva on October 2006 to: Discuss various issues related to prevention of PPH Develop recommendations

5 Methods Questions drafted by WHO staff (MPS, RH, Medicines, Policies and Standards) on various intervention described for prevention of atonic PPH (AMTSL and its components) Each question was subdivided to address skilled or non-skilled provider These questions and proposed outcomes to consider were sent to international panel of experts (58 experts in 6 WHO regions 37 responses received)

6 Methods Helped define critical outcomes vs. important but not critical Responses were reviewed by WHO core team External organization commissioned to review and grade the evidence to answer the questions, using the GRADE methodology

7 Methods Evidence-based recommendations in response to the questions asked were drafted Draft methodology, results, and recommendations were sent to sub-group of experts prior to their participation in the WHO Technical Consultation on PPH This draft and supporting evidence were reviewed at the Technical Consultation and changes made based on the recommendations of the expert panel.

8 Grades of Recommendation Assessment, Development and Evaluation 1. Assess the quality of evidence, prepare evidence profiles 2. Choose questions and rate importance of outcomes for decision making (before considering the evidence) 3. Assess the overall risk-benefit ratio, considering cost, access, and feasibility

9 Categories of quality High: Further research is very unlikely to change our confidence in the estimate of effect Moderate: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. +++ Low: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. ++ Very low: Any estimate of effect is very uncertain. +

10 Judgements about the balance between benefits and harms Strong recommendation: the panel is confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects. Weak recommendation: the panel concludes that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, but is not confident.

11 Critical beneficial outcomes Fewer maternal deaths Fewer admissions to intensive care unit Less blood loss > 500 ml Less blood loss > 1000 ml Less need for blood transfusion Less need for additional uterotonics Decreased mean blood loss Less postpartum anaemia Earlier establishmend of breast feeding Less anaemia in infancy What are the most important beneficial or priority outcomes of interventions to prevent PPH? Reduction in maternal mortality Less blood loss > 1000 ml Less use of blood transfusion Less use of uterotonics (added by the expert panel)

12 Evidence and Recommendations

13 1. Should AMTSL be offered by skilled attendants to all women 1 systematic review 5 trials UK, Ireland, UAE Different combinations of the components Recommendation: AMTSL should be offered by skilled attendants to all women Recommendation: STRONG Quality of evidence: MODERATE The panel does not recommend AMTSL by non-skilled attendants Remarks: Although no evidence was found for or against the use of AMTSL by non-skilled providers, the group placed high value on the potential risks such as uterine inversion that may result from inappropriate cord traction.

14 2. Should oxytocin (10 IU parenterally) or ergometrine/methylergometrine (0.25 mg parenterally) be offered in AMTSL? 2 systematic reviews > 9,000 women Oxytocin vs. ergometrine vs. syntometrine Oxytocin dose (2-10 IU), IM/IV Only one trial with direct comparison (1049 women) Recommendation: Oxytocin 10 IU IM should be offered to all women in preference to ergometrine If oxytocin is not available ergo/methylergo or syntometrine should be offered to women without hypertension and heart disease Recommendation: STRONG Quality of evidence: LOW Remarks: The recommendation places a high value on avoiding the adverse effects of ergometrine, and assumes similar benefit for oxytocin and ergometrine.

15 3. Should oral misoprostol (600 mcg) be offered instead of oxytocin (10 IU IM) in AMTSL? One systematic review 7 trials with direct comparison Largest trial > 18,000 women Recommendation: In the context of AMTSL skilled attendants should offer oxytocin in preference to oral misoprostol (600 mcg). Recommendation: STRONG Quality of evidence: HIGH Remarks: This recommendation places a high value on the relative benefits of oxytocin in preventing blood loss compared to misoprostol, as well as the increased adverse effects of misoprostol compared to oxytocin

16 4. Should sublingual misoprostol (600 mcg) be offered instead of oxytocin (10 IU IM)? One systematic review 2 trials < 200 women 1 trial compared to syntometrine Recommendation: In the context of AMTSL skilled attendants should not offer sublingual misoprostol for prevention of PPH in preference to oxytocin Recommendation: STRONG Quality of evidence: VERY LOW Remarks: Further research is needed to define the role of sublingual misoprostol administration for prevention of PPH

17 5. Should rectal misoprostol (600 mcg) be offered instead of oxytocin (10 IU IM)? Two systematic reviews Two oxytocin trials (one with 5 IU the other 10IU, 1221 women in total) One misoprostol trial (1620 women, auxiliary nurse-midwives) Recommendation: In the context of AMTSL skilled attendants should not offer rectal misoprostol for prevention of PPH in preference to oxytocin Recommendation: STRONG Quality of evidence: LOW Remarks: This recommendation places a high value on the known benefits of oxytocin and notes the significant uncertainty about whether rectal misoprostol is equivalent. Misoprostol has more adverse effects and a higher purchase cost.

18 6. Should carboprost 0.25 mg/sulprostone 0.5 mg) be offered instead of oxytocin (10 IU IM)? One systematic review Eight trials comparing injectable prostaglandins with other injectable uterotonics No study has compared carboprost/sulprostone with 10 IU oxytocin IM Recommendation: In the context of AMTSL skilled attendants should not offer carboprost/sulprostone in preference of oxytocin Recommendation: STRONG Quality of evidence: VERY LOW Remarks: This recommendation is based on the paucity of evidence comparing the two treatments and the known effectiveness of oxytocin.

19 7. In the absence of AMTSL, should uterotonics be used alone for prevention of PPH? Two systematic reviews Two oxytocin trials (one with 5 IU the other 10IU, 1221 women in total) One misoprostol trial (1620 women, auxiliary nurse-midwives) Recommendation: In the absence of AMTSL, a uterotonic drug (oxytocin or misoprostol) should be offered by a health worker trained in its use for prevention of PPH Recommendation: STRONG Quality of evidence: MODERATE Remarks: For misoprostol, this recommendation places a high value on the potential benefits of avoiding PPH and ease of administration of an oral drug in settings where other care is not available, but notes there is only one study. The only trial relevant to this recommendation used 600 mcg of misoprostol. The efficacy of lower doses has not been evaluated. There is still uncertainty about the lowest effective dose and optimal route of administration.

20 8. When should the cord be clamped to maximize benefits for mother and baby? One systematic review three additional trials varying definitions of of early clamping (10 sec 1 min) and delayed (2 (2 min stopping pulsation) no priority outcomes reported, but newborn anemia as an important outcome unclear whether timing of of cord clamping has an effect on PPH Recommendation: Because of the benefits to the baby, the cord should not be clamped earlier than necessary for applying cord traction in AMTSL. Recommendation: WEAK Quality of Evidence: LOW For the sake of clarity, it is estimated that this will normally take around 3 minutes Early clamping may be required if the baby is asphyxiated and requires immediate resuscitation.

21 9. Should the placenta be delivered by controlled traction in all women? Recommendation: Given the current evidence for AMTSL includes cord traction, the panel does not recommend any change in the current practice. Further research is needed. Recommendation: STRONG Quality of evidence: VERY LOW

22 Key discussion points Who is a skilled attendant? Discussed extensively in context of components of AMTSL Combines WHO, FIGO, ICM definition of 2004 with earlier definition by WHO, UNFPA, UNICEF and World Bank Older definition is broader and considers variable conditions on many low and middle-income developing countries Can include auxiliary nursemidwives, community midwives, village midwives and health visitors who have acquired appropriate skills, if specially trained

23 Key discussion points Implementation of recommendations Support from international professional organizations and partner agencies for changes in policy and regulation Work through regional and country offices (WHO and partners) Press release and co-publication Misoprostol in EDL for PPH indications Translation of recommendations Disseminaton and implementation of recommendations Develop a feedback mechanism Develop a virtual PPH network

24 Research Priorities Not in priority order What dose and route of administration of misoprostol are preferred for best riskbenefit ratio (in AMTSL and expectant management) Can oxytocin be administered safely by unskilled attendants? What is role of buccal and sublingual use of oxytocin? What is the effect of uterotonics on breastfeeding

25 Research Priorities With AMTSL, should misoprostol be used in addition to oxytocin What is the optimal time for cord clamping in the context of physiologic management and AMTSL? What is the optimum time for oxytocin administration in AMTSL to optimize the timing of cord clamping? What is the role of individual components of AMTSL?

26 Additional Research priorities Individual components of AMTSL Oxytocin (Uniject) vs. misoprostol where AMTSL is not (or will not) be practiced Use of a validated blood measurement drape

27 Implications Preventing PPH where skilled provider present: AMTSL, Oxytocin preferable Use Ergometrine or Methylergometrine only if oxytocin not available. However, no similar guidance on use of misoprostol as an alternative if others are not available Oral, sublingual, or rectal misoprostol or carboprost should not be used instead of oxytocin. From practical and logistics perspectives: Programs should promote AMTSL universally with Oxytocin FIGI-ICM guidelines are fully supported.

28 Implications Births not attended by skilled providers WHO strongly recommends use of oxytocin or misoprostol provided by trained health workers even when all components of AMTSL cannot be provided Any trained health worker (not skilled attendant) who is present may provide Oxytocin or misoprostol after birth of baby. By implication, WHO strongly recommends the provision of misoprostol by trained health workers (eg community health volunteers) to pregnant women for use after childbirth WHO is pursuing inclusion of prevention of pph as an indication for misoprostol in the WHO essential medicines list.

29 Implications The panel made a weak recommendation on delayed clamping of cord In practical terms: following childbirth, give oxytocin, proceed to dry and warm baby, await uterine contraction (which will usually occur in 2-3 minutes), clamp and cut cord, perform CCT, deliver placenta, and perform uterine massage Cord should not be clamped immediately but after uterine contraction occurs, in indication that CCT should then begin

30 Next Steps Paradigm Shift is occurring with new activities and programs available to save lives PPH prevention strategies are expanding to include home/community as well as facilities AMTSL is becoming available to a broader group of health workers provided they are trained to competency in the skills. Misoprostol is accepted as a strategy for PPH prevention Oxytocin will be more accessible to communities with Uniject and with the temperature monitor (VVM)

31 Program Implications and Next Steps Discussion: Panel and Audience Thank you